CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02742727
Recruitment Status : Recruiting
First Posted : April 19, 2016
Last Update Posted : December 6, 2016
The First People's Hospital of Hefei
Hefei Binhu Hospital
Information provided by (Responsible Party):
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

March 31, 2016
April 19, 2016
December 6, 2016
March 2016
March 2017   (Final data collection date for primary outcome measure)
Adverse events attributed to the administration of the anti-CD7 CAR-pNK cells [ Time Frame: 2 years ]
Determine the toxicity profile of the CD7 targeted CAR-pNK cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0.
Same as current
Complete list of historical versions of study NCT02742727 on Archive Site
  • Clinical response to CD7 CAR-pNK cell infusions [ Time Frame: Safety follow-up is 100 days from last CAR-pNK infusion ]
    Patients with measurable disease will be assessed for the response of their disease to CD7 CAR-pNK cell treatment.
  • Determine the existence of CD7-CAR-pNK in vivo [ Time Frame: 1 year ]
Same as current
Not Provided
Not Provided
CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma
Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma
The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with CD7 positive relapsed or refractory Leukemia and Lymphoma.
Not Provided
Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Acute Myeloid Leukemia
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  • T-cell Prolymphocytic Leukemia
  • T-cell Large Granular Lymphocytic Leukemia
  • Peripheral T-cell Lymphoma, NOS
  • Angioimmunoblastic T-cell Lymphoma
  • Extranodal NK/T-cell Lymphoma, Nasal Type
  • Enteropathy-type Intestinal T-cell Lymphoma
  • Hepatosplenic T-cell Lymphoma
Biological: anti-CD7 CAR-pNK cells
The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD7 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD7.
Other Name: chimeric antigen receptor NK cells with specificity for CD7
Experimental: CAR-pNK Cell immunotherapy
Enrolled patients will receive CAR-pNK cell immunotherapy with a novel specific chimeric antigen receptor targeting CD7 antigen by infusion.
Intervention: Biological: anti-CD7 CAR-pNK cells
Del Zotto G, Marcenaro E, Vacca P, Sivori S, Pende D, Della Chiesa M, Moretta F, Ingegnere T, Mingari MC, Moretta A, Moretta L. Markers and function of human NK cells in normal and pathological conditions. Cytometry B Clin Cytom. 2017 Mar;92(2):100-114. doi: 10.1002/cyto.b.21508. Epub 2017 Feb 12. Review.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
March 2018
March 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Male and female subjects with CD7+ malignancies in patients with no available curative treatment options who have limited prognosis (several months to < 2 year survival) with currently available therapies will be enrolled:

  1. Eligible diseases: CD7 positive relapsed or refractory Leukemia and Lymphoma. ᅳ Acute myeloid leukemia, previously identified as CD7+ ᅳ Precursor T lymphoblast leukemia/lymphoma ᅳ T-cell prolymphocytic leukemia ᅳ T-cell large granular lymphocytic leukemia ᅳ Peripheral T-cell lymphoma, NOS ᅳ Angioimmunoblastic T-cell lymphoma ᅳ Extranodal NK/T-cell lymphoma, nasal type ᅳ Enteropathy-type intestinal T-cell lymphoma ᅳ Hepatosplenic T-cell lymphoma
  2. Patients 18 years of age or older, and must have a life expectancy > 12 weeks.
  3. CD7 is expressed in malignancy tissues by immuno-histochemical (IHC) or Flow cytometry.
  4. Assessable disease as measured by laboratory and bone marrow examinations.
  5. Eastern cooperative oncology group (ECOG) performance status of 0-2 or karnofsky performance status (KPS) score is higher than 60.
  6. Females of child-bearing potential must have a negative pregnancy test and all subjects must agree to use an effective method of contraception for up to two weeks after the last infusion of CAR-pNK cells.
  7. Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: serum creatinine ≤ 2.5mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5×upper limit of normal, serum total bilirubin ≤ 2.0mg/dL. These tests must be conducted within 7 days prior to registration.
  8. Ability to give informed consent.

Exclusion Criteria:

  1. Patients with symptomatic central nervous system (CNS) involvement.
  2. Pregnant or nursing women may not participate.
  3. Known HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
  4. Serious illness or medical condition which would not permit the patient to be managed according to the protocol, including active uncontrolled infection, major cardiovascular, coagulation disorders, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive/restrictive pulmonary disease, or psychiatric or emotional disorders.
  5. Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
  6. Previously treatment with any gene therapy products.
  7. The existence of unstable or active ulcers or gastrointestinal bleeding.
  8. Patients with a history of organ transplantation or are waiting for organ transplantation.
  9. Patients need anticoagulant therapy (such as warfarin or heparin).
  10. Patients need long-term antiplatelet therapy (aspirin at a dose > 300mg/d; clopidogrel at a dose > 75mg/d).
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact: Lin Yang, Ph.D. 86-512-65922190
Not Provided
Plan to Share IPD: Yes
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
  • The First People's Hospital of Hefei
  • Hefei Binhu Hospital
Principal Investigator: Lin Yang, Ph.D. PersonGen BioTherapeutics (Suzhou) Co., Ltd.
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
December 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP